Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000527222 | SCV000645529 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2024-01-16 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001560044 | SCV001782378 | uncertain significance | not provided | 2020-07-30 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Splice predictors suggests this variant may impact gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown.; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 32459320) |
Prevention |
RCV004553236 | SCV004739535 | uncertain significance | JAG1-related disorder | 2024-01-03 | no assertion criteria provided | clinical testing | The JAG1 c.3281G>A variant is predicted to result in the amino acid substitution p.Arg1094Gln. This variant was reported in an individual with hypothyroidism (Yamaguchi et al 2020. PubMed ID: 32459320). This variant is reported in 0.023% of alleles in individuals of European (Non-Finnish) descent in gnomAD, which is likely too common to be a primary cause of disease. Although we suspect this variant may be benign, at this time, the clinical significance is uncertain due to the absence of conclusive functional and genetic evidence. |